(Q36007339)

11 August 2017

1 reference

title

Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway (English)

1 reference

11 August 2017

Michael J Grace

1

1 reference

11 August 2017

David Cutler

series ordinal

2

1 reference

11 August 2017

publication date

1 November 2004

1 reference

Antiviral Chemistry & Chemotherapy

11 August 2017

published in

1 reference

11 August 2017

volume

15

1 reference

11 August 2017

issue

6

1 reference

11 August 2017

page(s)

287-297

1 reference

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Regulation of gene expression by pegylated IFN-alpha2b and IFN-alpha2b in human peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Chondroosseous dysplasia in severe combined immunodeficiency due to adenosine deaminase deficiency (chondroosseous dysplasia in ADA deficiency scid)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Evolving role of pegylated interferons in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Structural and biologic characterization of pegylated recombinant IFN-alpha2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Inhibition of immune functions by antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

The treatment of chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

STATs: signal transducers and activators of transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Biomedical and biotechnological applications of PEG- and PM-modified proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Development of pegylated interferons for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Regulation of interferon-alpha responsiveness by the duration of Janus kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Management of viral hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Pegylated interferons for the treatment of chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Biophysical analysis of the interaction of human ifnar2 expressed in E. coli with IFNalpha2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Structure of the interferon-receptor complex determined by distance constraints from double-mutant cycles and flexible docking

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Transcriptional responses to polypeptide ligands: the JAK-STAT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Carboxyalkylated histidine is a pH-dependent product of pegylation with SC-PEG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Clinical significance of hepatitis C virus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500601

10.1177/095632020401500601

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference